These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 14434441)

  • 1. Studies on the development of natural immunity to poliomyelitis in Louisiana. VI. The incidence of poliovirus infections during 1958 as an indication of the effect of Salk-type vaccine on virus dissemination.
    POTASH L; GELFAND HM; FOX JP
    Am J Hyg; 1960 May; 71():418-26. PubMed ID: 14434441
    [No Abstract]   [Full Text] [Related]  

  • 2. Studies on the development of natural immunity to poliomyelitis in Louisiana. III. The serologic response to commercially produced "Salk vaccine" of children totally or partially susceptible to poliovirus infection.
    GELFAND HM; LeBLANC DR; FOX JP; POTASH L
    Am J Hyg; 1959 Nov; 70():303-11. PubMed ID: 13827181
    [No Abstract]   [Full Text] [Related]  

  • 3. Studies onthe development of natural immunity to poliomyelitis in Louisiana. IV. Natural infections with polioviruses following immunization with a formalin-inactivated vaccine.
    GELFAND HM; LeBLANC DR; POTASH L; FOX JP
    Am J Hyg; 1959 Nov; 70():312-27. PubMed ID: 13827182
    [No Abstract]   [Full Text] [Related]  

  • 4. Immunity to poliomyelitis in Guatemala: a serological and virological survey.
    HORSTMANN DM; SAENZ AC; OPTON EM
    Bull World Health Organ; 1960; 22(3-4):255-62. PubMed ID: 14403224
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Some results of the work on mass immunization in the Soviet Union with live poliovirus vaccine prepared from Sabin strains.
    CHUMAKOV MP
    Bull World Health Organ; 1961; 25(1):79-91. PubMed ID: 13879389
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Review of the Louisiana State Board of Health experience with the use of Salk vaccine and comments on the Sabin oral polio vaccine.
    HEDMEG A
    J La State Med Soc; 1963 Feb; 115():41-7. PubMed ID: 13963684
    [No Abstract]   [Full Text] [Related]  

  • 7. Vaccination against poliomyelitis in Poland with types 1 and 3 attenuated viruses of Koprowski. 1. Virological studies of the vaccine strains and serological studies of the vaccinated population.
    PRZESMYCKI F; DOBROWOLSKA H; MIRSKI B; WIOR H; STANCZYK R; ZALESKA H
    Bull World Health Organ; 1962; 26(6):733-43. PubMed ID: 14489069
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Formation and persistence of antibodies against poliomyelitis after vaccinations with Salk vaccine. A contribution to the value and limitations of Salk vaccinations].
    BUERGIN-WOLFF A; BERGER E
    Schweiz Med Wochenschr; 1960 Jun; 90():633-7. PubMed ID: 13805708
    [No Abstract]   [Full Text] [Related]  

  • 9. [Preparation and control of the Salk vaccine against poliomyelitis].
    DE SOMER P
    Belg Tijdschr Geneesk; 1956 Aug; 12(16):841-52. PubMed ID: 13355838
    [No Abstract]   [Full Text] [Related]  

  • 10. Present status of immunization against poliomyelitis (Salk vaccine versus living, attenuated virus).
    WEISS C
    J Albert Einstein Med Cent (Phila); 1956 Sep; 4(4):159-60. PubMed ID: 13357446
    [No Abstract]   [Full Text] [Related]  

  • 11. A phase contrast microprecipitin test with poliovirus antigens. II. Occurrence and development of microprecipitin antibody after natural inapparent infections, after inoculation of Salk vaccine, after feeding of attenuated live poliovirus vaccine, and in disease caused by polioviruses and other enteroviruses.
    EGGERS HJ; SABIN AB
    Arch Gesamte Virusforsch; 1961; 11():152-75. PubMed ID: 13725917
    [No Abstract]   [Full Text] [Related]  

  • 12. [Clinical observations on children vaccinated against poliomyelitis (Salk vaccine)].
    FUTER DS; IAMPOL'SKAIA EI
    Sov Med; 1960 Jun; 24():9-16. PubMed ID: 13825787
    [No Abstract]   [Full Text] [Related]  

  • 13. Effectiveness of Salk vaccine in reducing nonparalytic poliomyelitis in a large urban epidemic.
    MARINE WM; CHIN TD; GRAVELLE CR; SOERGEL ME
    N Engl J Med; 1961 May; 264():903-7. PubMed ID: 13766783
    [No Abstract]   [Full Text] [Related]  

  • 14. Some statistical aspects of safety testing the Salk poliomyelitis vaccine.
    CORNFIELD J; HALPERIN M; MOORE F
    Public Health Rep (1896); 1956 Oct; 71(10):1045-56. PubMed ID: 13370807
    [No Abstract]   [Full Text] [Related]  

  • 15. [On neutralizing antibodies before and after vaccination against poliomyelitis with Salk vaccine].
    GILLERT KE; GRUETZNER L; HARTMANN H
    Zentralbl Bakteriol; 1960 Feb; 177():289-98. PubMed ID: 13850076
    [No Abstract]   [Full Text] [Related]  

  • 16. Unpredictability of antibody response of infants to injections of Salk poliomyelitis vaccine.
    CRAMBLETT HG; FOMON SJ
    J Pediatr; 1961 Jun; 58():779-84. PubMed ID: 13696225
    [No Abstract]   [Full Text] [Related]  

  • 17. Effectiveness of Salk vaccine. Analysis of virologically confirmed cases of paralytic and nonparalytic poliomyelitis.
    MELNICK JL; BENYESH-MELNICK M; PENA R; YOW M
    JAMA; 1961 Apr; 175():1159-62. PubMed ID: 13769273
    [No Abstract]   [Full Text] [Related]  

  • 18. Review of Salk vaccine use in Delaware.
    HUDSON FI
    Del State Med J; 1956 Sep; 28(9):215-6. PubMed ID: 13365302
    [No Abstract]   [Full Text] [Related]  

  • 19. Cutaneous eruptions after use of Salk poliomyelitis vaccine.
    STROUD GM; BRODELL HL; LASCHEID WP; POTTS LW
    J Am Med Assoc; 1958 Jan; 166(3):251-3. PubMed ID: 13491335
    [No Abstract]   [Full Text] [Related]  

  • 20. A review of the effectiveness of Salk vaccine in Alberta with special reference to the outbreak of poliomyelitis in 1960.
    SMITH ES
    Can J Public Health; 1961 Nov; 52():467-73. PubMed ID: 13914212
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.